Pathophysiology of Takotsubo syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology - Part 1: overview and the central role for catecholamines and sympathetic nervous system.
Beta-adrenergic signalling
Catecholamine
Electrophysiology
G-protein coupled receptor kinase
Inflammation
Metabolism
Pathophysiology
Takotsubo syndrome
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
04
12
2021
received:
25
10
2020
accepted:
07
12
2021
pubmed:
16
12
2021
medline:
2
4
2022
entrez:
15
12
2021
Statut:
ppublish
Résumé
This is the first part of a scientific statement from the Heart Failure Association (HFA) of the European Society of Cardiology focused upon the pathophysiology of Takotsubo syndrome and is complimentary to the previous HFA position statement on Takotsubo syndrome which focused upon clinical management. In part 1 we provide an overview of the pathophysiology of Takotsubo syndrome and fundamental questions to consider. We then review and discuss the central role of catecholamines and the sympathetic nervous system in the pathophysiology, and the direct effects of high surges in catecholamines upon myocardial biology including β-adrenergic receptor signalling, G-protein coupled receptor kinases, cardiomyocyte calcium physiology, myofilament physiology, cardiomyocyte gene expression, myocardial electrophysiology and arrhythmogenicity, myocardial inflammation, metabolism and energetics. The integrated effects upon ventricular haemodynamics are discussed and integrated into the pathophysiological model.
Substances chimiques
Catecholamines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
257-273Subventions
Organisme : British Heart Foundation
ID : PG/15/108/31928
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/16/39/32174
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, et al. Current state of knowledge on Takotsubo syndrome: a position statement from the taskforce on Takotsubo syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2016;18:8-27.
Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International expert consensus document on Takotsubo syndrome (part I): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J. 2018;39:2032-46.
Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, et al. Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373:929-38.
Redfors B, Vedad R, Angerås O, Råmunddal T, Petursson P, Haraldsson I, et al. Mortality in takotsubo syndrome is similar to mortality in myocardial infarction - a report from the SWEDEHEART. Int J Cardiol. 2015;185:282-9.
Omerovic E, Citro R, Bossone E, Redfors B, Backs J, Bruns B, Ciccarelli M, Couch LS, Dawson D, Grassi G, Iacoviello M, Parodi G, Schneider B, Templin C, Ghadri JR, Thum T, Chioncel O, Tocchetti CG, van der Velden J, Heymans S, Lyon AR. Pathophysiology of Takotsubo syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology - Part 2: vascular pathophysiology, gender and sex hormones, genetics, chronic cardiovascular problems and clinical implications. Eur J Heart Fail. 2022;24:274-86.
Kurowski V, Kaiser A, Von Hof K, Killermann DP, Mayer B, Hartmann F, et al. Apical and midventricular transient left ventricular dysfunction syndrome (Tako-Tsubo cardiomyopathy): frequency, mechanisms, and prognosis. Chest. 2007;132:809-16.
Madias JE. Why the current diagnostic criteria of Takotsubo syndrome are outmoded: a proposal for new criteria. Int J Cardiol. 2014;174:468-70.
Scantlebury DC, Prasad A. Diagnosis of Takotsubo cardiomyopathy. Circ J. 2014;78:2129-39.
Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J. 2008;155:408-17.
Abe Y, Kondo M, Matsuoka R, Araki M, Dohyama K, Tanio H. Assessment of clinical features in transient left ventricular apical ballooning. J Am Coll Cardiol. 2003;41:737-42.
Bybee KA, Kara T, Prasad A, Lerman A, Barsness GW, Scott Wright R, et al. Systematic review: transient left ventricular apical ballooning: a syndrome that mimics ST-segment elevation myocardial infarction. Ann Intern Med. 2004;141:858-65.
Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association scientific statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807-16.
Kawai S, Kitabatake A, Tomoike H; Takotsubo Cardiomyopathy Group. Guidelines for diagnosis of takotsubo (ampulla) cardiomyopathy. Circ J 2007;71:990-992.
Wittstein IS. Stress cardiomyopathy: a syndrome of catecholamine-mediated myocardial stunning? Cell Mol Neurobiol. 2012;32:847-57.
Schultz T, Shao Y, Redfors B, Bergmann Sverrisdóttir Y, Råmunddal T, Albertsson P, et al. Stress-induced cardiomyopathy in Sweden: evidence for different ethnic predisposition and altered cardio-circulatory status. Cardiology. 2012;122:180-6.
Parodi G, Citro R, Bellandi B, Provenza G, Marrani M, Bossone E. Revised clinical diagnostic criteria for Tako-tsubo syndrome: the Tako-tsubo Italian Network proposal. Int J Cardiol. 2014;172:282-3.
Redfors B, Ali A, Shao Y, Lundgren J, Gan LM, Omerovic E. Different catecholamines induce different patterns of takotsubo-like cardiac dysfunction in an apparently afterload dependent manner. Int J Cardiol. 2014;174:330-6.
Ghadri JR, Sarcon A, Diekmann J, Bataiosu DR, Cammann VL, Jurisic S, et al. Happy heart syndrome : role of positive emotional stress in takotsubo syndrome. Eur Heart J. 2016;37:2823-9.
Scally C, Rudd A, Mezincescu A, Wilson H, Srivanasan J, Horgan G, et al. Persistent long-term structural, functional, and metabolic changes after stress-induced (Takotsubo) cardiomyopathy. Circulation. 2018;137:1039-48.
Wischnewsky MB, Candreva A, Bacchi B, Cammann VL, Kato K, Szawan KA, et al. Prediction of short- and long-term mortality in takotsubo syndrome: the InterTAK prognostic score. Eur J Heart Fail. 2019;21:1469-72.
Citro R, Radano I, Parodi G, Di Vece D, Zito C, Novo G, et al. Long-term outcome in patients with Takotsubo syndrome presenting with severely reduced left ventricular ejection fraction. Eur J Heart Fail. 2019;21:781-9.
Kato K, Di Vece D, Cammann VL, Micek J, Szawan KA, Bacchi B, et al. Takotsubo recurrence: morphological types and triggers and identification of risk factors. J Am Coll Cardiol. 2019;73:982-4.
Madhavan M, Borlaug BA, Lerman A, Rihal CS, Prasad A. Stress hormone and circulating biomarker profile of apical ballooning syndrome (Takotsubo cardiomyopathy): insights into the clinical significance of B-type natriuretic peptide and troponin levels stress hormone and circulating biomarker profile of apic. Heart. 2009;95:1436-41.
Fröhlich GM, Schoch B, Schmid F, Keller P, Sudano I, Lüscher TF, et al. Takotsubo cardiomyopathy has a unique cardiac biomarker profile: NT-proBNP/myoglobin and NT-proBNP/troponin T ratios for the differential diagnosis of acute coronary syndromes and stress induced cardiomyopathy. Int J Cardiol. 2012;154:328-32.
Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002;106:2913-8.
Stiermaier T, Santoro F, Graf T, Guastafierro F, Tarantino N. Prognostic value of N-terminal pro-B-type natriuretic peptide in Takotsubo syndrome. Clin Res Cardiol 2018;107:597-606.
Redfors B, Shao Y, Ali A, Omerovic E. Current hypotheses regarding the pathophysiology behind the takotsubo syndrome. Int J Cardiol. 2014;177:771-9.
Akashi YJ, Nef HM, Lyon AR. Epidemiology and pathophysiology of Takotsubo syndrome. Nat Rev Cardiol. 2015;12:387-97.
Madias JE. Speculations on the pathophysiology of Takotsubo syndrome. Expert Rev Cardiovasc Ther. 2015;13:239-40.
Pelliccia F, Kaski JC, Crea F, Camici PG. Pathophysiology of Takotsubo syndrome. Circulation. 2017;135:2426-41.
Tranter MH, Wright PT, Sikkel MB, Lyon AR. Takotsubo cardiomyopathy: the pathophysiology. Heart Fail Clin. 2013;9:187-96.
Yoshikawa T. Takotsubo cardiomyopathy, a new concept of cardiomyopathy: clinical features and pathophysiology. Int J Cardiol. 2015;182:297-303.
Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International expert consensus document on Takotsubo syndrome (part II): diagnostic workup, outcome, and management. Eur Heart J. 2018;39:2047-62.
Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Cardiovascular manifestations of phaeochromocytoma. J Hypertens. 2011;29:2049-60.
Agarwal V, Kant G, Hans N, Messerli FH. Takotsubo-like cardiomyopathy in pheochromocytoma. Int J Cardiol. 2011;153:241-8.
Redfors B, Shao Y, Omerovic E. Stress-induced cardiomyopathy (Takotsubo) - broken heart and mind? Vasc Heal Risk Manag. 2013;9:149-54.
Abraham J, Mudd JO, Kapur N, Klein K, Champion HC, Wittstein IS. Stress cardiomyopathy after intravenous administration of catecholamines and beta-receptor agonists. J Am Coll Cardiol. 2009;53:1320-5.
Redfors B, Shao Y, Omerovic E. Stress-induced cardiomyopathy in a patient with chronic spinal cord transection at the level of C5: endocrinologically mediated catecholamine toxicity. Int J Cardiol 2012;159:e61-e62.
Kume T, Kawamoto T, Okura H, Toyota E, Neishi Y, Watanabe N, et al. Local release of catecholamines from the hearts of patients with tako-tsubo-like left ventricular dysfunction. Circ J. 2008;72:106-8.
Wittstein IS, Thiemann DR, Lima J, Baughman KL, Schulman SP, Gerstenblith G, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med. 2005;352:539-48.
Vaccaro A, Despas F, Delmas C, Lairez O, Lambert E, Lambert G, et al. Direct evidences for sympathetic hyperactivity and baroreflex impairment in tako tsubo cardiopathy. PLoS One. 2014;9:e93278.
Shao Y, Redfors B, Scharin Tang M, Mollmann H, Troidl C, Szardien S, et al. Novel rat model reveals important roles of β-adrenoreceptors in stress-induced cardiomyopathy. Int J Cardiol. 2013;168:1943-50.
Sachdeva J, Dai W, Kloner RA. Functional and histological assessment of an experimental model of Takotsubo's cardiomyopathy. J Am Heart Assoc. 2014;3:e000921.
Paur H, Wright PT, Sikkel MB, Tranter MH, Mansfield C, O'Gara P, et al. High levels of circulating epinephrine trigger apical cardiodepression in a β2-adrenergic receptor/Gi-dependent manner: a new model of takotsubo cardiomyopathy. Circulation. 2012;126:697-706.
Novitzky D, Wicomb WN, Cooper DK, Rose AG, Reichart B. Prevention of myocardial injury during brain death by total cardiac sympathectomy in the Chacma baboon. Ann Thorac Surg. 1986;41:520-4.
van Bilsen M, Patel HC, Bauersachs J, Böhm M, Borggrefe M, Brutsaert D, et al. The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2017;19:1361-78.
Jaguszewski M, Osipova J, Ghadri JR, Napp LC, Widera C, Franke J, et al. A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction. Eur Heart J. 2014;35:999-1006.
Lehmann LH, Rostosky JS, Buss SJ, Kreusser MM, Krebs J, Mier W, et al. Essential role of sympathetic endothelin a receptors for adverse cardiac remodeling. Proc Natl Acad Sci U S A. 2014;111:13499-504.
Redfors B, Angeras O, Ramunddal T, Dworeck C, Haraldsson I, Ioanes D, et al. 17-year trends in incidence and prognosis of cardiogenic shock in patients with acute myocardial infarction in western Sweden. Int J Cardiol. 2015;185:256-62.
Ali A, Redfors B, Lundgren J, Alkhoury J, Oras J, Gan LM, et al. Effects of pretreatment with cardiostimulants and beta-blockers on isoprenaline-induced takotsubo-like cardiac dysfunction in rats. Int J Cardiol. 2019;281:99-104.
Rosenbaum DM, Rasmussen SGF, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009;459:356-63.
Evans B, Sato M, Sarwar M, Hutchinson D, Summers R. Ligand-directed signalling at β-adrenoceptors. Br J Pharmacol. 2010;159:1022-38.
Woo AYH, Xiao R. β-Adrenergic receptor subtype signaling in heart: from bench to bedside. Acta Pharmacol Sin. 2012;33:335-41.
Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature. 1997;390:88-91.
Liu R, Ramani B, Soto D, De Arcangelis V, Xiang Y. Agonist dose-dependent phosphorylation by protein kinase A and G protein-coupled receptor kinase regulates β2 adrenoceptor coupling to Gi proteins in cardiomyocytes. J Biol Chem. 2009;284:32279-87.
Lyon AR, Rees PSC, Prasad S, Poole-Wilson PA, Harding SE. Stress (Takotsubo) cardiomyopathy - a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med. 2008;5:22-9.
Land S, Niederer SA, Louch WE, Røe AT, Aronsen JM, Stuckey DJ, et al. Computational modeling of Takotsubo cardiomyopathy: effect of spatially varying β-adrenergic stimulation in the rat left ventricle. Am J Physiol Heart Circ Physiol. 2014;307:H1487-96.
Wright PT, Bhogal NK, Diakonov I, Pannell LMK, Perera RK, Bork NI, et al. Cardiomyocyte membrane structure and cAMP compartmentation produce anatomical variation in β2AR-cAMP responsiveness in murine hearts. Cell Rep. 2018;23:459-69.
Couch LS, Fiedler J, Chick G, Clayton R, Dries E, Wienecke LM, et al. Circulating microRNAs predispose to takotsubo syndrome following high-dose adrenaline exposure. Cardiovasc Res. 2021. https://doi.org/10.1093/cvr/cvab210.
Nef HM, Mollmann H, Akashi YJ, Hamm CW. Mechanisms of stress (Takotsubo) cardiomyopathy. Nat Rev Cardiol. 2010;7:187-93.
Penela P, Ribas C, Mayor F. Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. Cell Signal. 2003;15:973-81.
Sorriento D, Ciccarelli M, Santulli G, Illario M, Trimarco B, Iaccarino G. Trafficking GRK2: cellular and metabolic consequences of GRK2 subcellular localization. Transl Med UniSa. 2014;10:3-7.
Matkovich SJ, Diwan A, Klanke JL, Hammer DJ, Marreez Y, Odley AM, et al. Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and β-adrenergic signaling. Circ Res. 2006;99:996-1003.
Franco A, Sorriento D, Gambardella J, Pacelli R, Prevete N, Procaccini C, et al. GRK2 moderates the acute mitochondrial damage to ionizing radiation exposure by promoting mitochondrial fission/fusion. Cell Death Discov. 2018;4:25.
Fusco A, Santulli G, Sorriento D, Cipolletta E, Garbi C, Dorn GW, et al. Mitochondrial localization unveils a novel role for GRK2 in organelle biogenesis. Cell Signal. 2012;24:468-75.
Nakano T, Onoue K, Nakada Y, Nakagawa H, Kumazawa T, Ueda T, et al. Alteration of β-adrenoceptor signaling in left ventricle of acute phase Takotsubo syndrome: a human study. Sci Rep. 2018;8:12731.
Bychkov E, Zurkovsky L, Garret MB, Ahmed MR, Gurevich EV. Distinct cellular and subcellular distributions of G protein-coupled receptor kinase and arrestin isoforms in the striatum. PLoS One. 2012;7:e48912.
Martini JS, Raake P, Vinge LE, DeGeorge B, Chuprun JK, Harris DM, et al. Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci U S A. 2008;105:12457-62.
Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, et al. A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure. Nat Med. 2008;14:510-7.
Spinelli L, Trimarco V, Di Marino S, Marino M, Iaccarino G, Trimarco B. L41Q polymorphism of the G protein coupled receptor kinase 5 is associated with left ventricular apical ballooning syndrome. Eur J Heart Fail. 2010;12:13-6.
Novo G, Giambanco S, Guglielmo M, Arvigo L, Sutera MR, Giambanco F, et al. G-protein-coupled receptor kinase 5 polymorphism and Takotsubo cardiomyopathy. J Cardiovasc Med. 2015;16:639-43.
Figtree GA, Bagnall RD, Abdulla I, Buchholz S, Galougahi KK, Yan W, et al. No association of G-protein-coupled receptor kinase 5 or beta-adrenergic receptor polymorphisms with Takotsubo cardiomyopathy in a large Australian cohort. Eur J Heart Fail. 2013;15:730-3.
Wachter SB, Gilbert EM. Beta-adrenergic receptors, from their discovery and characterization through their manipulation to beneficial clinical application. Cardiology. 2012;122:104-12.
Borchert T, Hübscher D, Guessoum CI, Lam TDD, Ghadri JR, Schellinger IN, et al. Catecholamine-dependent β-adrenergic signaling in a pluripotent stem cell model of Takotsubo cardiomyopathy. J Am Coll Cardiol. 2017;70:975-91.
Kolodzinska A, Czarzasta K, Szczepankiewicz B, Glowczynska R, Fojt A, Ilczuk T, et al. Toll-like receptor expression and apoptosis morphological patterns in female rat hearts with takotsubo syndrome induced by isoprenaline. Life Sci. 2018;199:112-21.
Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol. 1985;17:291-306.
Nef HM, Möllmann H, Kostin S, Troidl C, Voss S, Weber M, et al. Tako-Tsubo cardiomyopathy: intraindividual structural analysis in the acute phase and after functional recovery. Eur Heart J. 2007;28:2456-64.
Szardien S, Mollmann H, Willmer M, Liebetrau C, Voss S, Troidl C, et al. Molecular basis of disturbed extracellular matrix homeostasis in stress cardiomyopathy. Int J Cardiol. 2013;168:1685-8.
van der Velden J, Stienen GJM. Cardiac disorders and pathophysiology of sarcomeric proteins. Physiol Rev. 2019;99:381-426.
Davis J, Davis LC, Correll RN, Makarewich CA, Schwanekamp JA, Moussavi-Harami F, et al. A tension-based model distinguishes hypertrophic versus dilated cardiomyopathy. Cell. 2016;165:1147-59.
Tardiff JC, Carrier L, Bers DM, Poggesi C, Ferrantini C, Coppini R, et al. Targets for therapy in sarcomeric cardiomyopathies. Cardiovasc Res. 2015;105:457-70.
Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016;351:617-21.
Planelles-Herrero VJ, Hartman JJ, Robert-Paganin J, Malik FI, Houdusse A. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil. Nat Commun. 2017;8:190.
Kreusser MM, Lehmann LH, Keranov S, Hoting MO, Oehl U, Kohlhaas M, et al. Cardiac CaM kinase II genes δ and γ contribute to adverse remodeling but redundantly inhibit calcineurin-induced myocardial hypertrophy. Circulation. 2014;130:1262-73.
Lehmann LH, Jebessa ZH, Kreusser MM, Horsch A, He T, Kronlage M, et al. A proteolytic fragment of histone deacetylase 4 protects the heart from failure by regulating the hexosamine biosynthetic pathway. Nat Med. 2018;24:62-72.
Dewenter M, Neef S, Vettel C, Lämmle S, Beushausen C, Zelarayan LC, et al. Calcium/calmodulin-dependent protein kinase II activity persists during chronic β-adrenoceptor blockade in experimental and human heart failure. Circ Hear Fail. 2017;10:e003840.
Backs J, Song K, Bezprozvannaya S, Chang S, Olson EN. CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J Clin Invest. 2006;116:1853-64.
Backs J, Worst BC, Lehmann LH, Patrick DM, Jebessa Z, Kreusser MM, et al. Selective repression of MEF2 activity by PKA-dependent proteolysis of HDAC4. J Cell Biol. 2011;195:403-15.
Veltkamp R, Uhlmann S, Marinescu M, Sticht C, Finke D, Gretz N, et al. Experimental ischaemic stroke induces transient cardiac atrophy and dysfunction. J Cachexia Sarcopenia Muscle. 2019;10:54-62.
Tsuchihashi K, Ueshima K, Uchida T, Oh-mura N, Kimura K, Owa M, et al. Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction. Angina pectoris-myocardial infarction investigations in Japan. J Am Coll Cardiol. 2001;38:11-8.
Pant S, Deshmukh A, Mehta K, Badheka AO, Tuliani T, Patel NJ, et al. Burden of arrhythmias in patients with Takotsubo cardiomyopathy (apical ballooning syndrome). Int J Cardiol. 2013;170:64-8.
Schneider B, Athanasiadis A, Schwab J, Pistner W, Gottwald U, Schoeller R, et al. Complications in the clinical course of tako-tsubo cardiomyopathy. Int J Cardiol. 2014;176:199-205.
Stiermaier T, Santoro F, Eitel C, Graf T, Moller C, Tarantino N, et al. Prevalence and prognostic relevance of atrial fibrillation in patients with Takotsubo syndrome. Int J Cardiol. 2017;245:156-61.
Jesel L, Berthon C, Messas N, Lim HS, Girardey M, Marzak H, et al. Ventricular arrhythmias and sudden cardiac arrest in Takotsubo cardiomyopathy: incidence, predictive factors, and clinical implications. Heart Rhythm. 2018;15:1171-8.
Jesel L, Berthon C, Messas N, Lim HS, Girardey M, Marzak H, et al. Atrial arrhythmias in Takotsubo cardiomyopathy: incidence, predictive factors, and prognosis. Europace. 2019;21:298-305.
Workman AJ. Cardiac adrenergic control and atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol. 2010;381:235-49.
Stiermaier T, Graf T, Möller C, Eitel C, Ledwoch J, Desch S, et al. Transient left atrial dysfunction is a feature of Takotsubo syndrome. J Cardiovasc Magn Reson. 2017;19:15.
Madias C, Fitzgibbons TP, Alsheikh-Ali AA, Bouchard JL, Kalsmith B, Garlitski AC, et al. Acquired long QT syndrome from stress cardiomyopathy is associated with ventricular arrhythmias and torsades de pointes. Heart Rhythm. 2011;8:555-61.
Perazzolo Marra M, Zorzi A, Corbetti F, De Lazzari M, Migliore F, Tona F, et al. Apicobasal gradient of left ventricular myocardial edema underlies transient T-wave inversion and QT interval prolongation (Wellens' ECG pattern) in Tako-Tsubo cardiomyopathy. Heart Rhythm. 2013;10:70-7.
Migliore F, Zorzi A, Perazzolo Marra M, Iliceto S, Corrado D. Myocardial edema as a substrate of electrocardiographic abnormalities and life-threatening arrhythmias in reversible ventricular dysfunction of takotsubo cardiomyopathy: imaging evidence, presumed mechanisms, and implications for therapy. Heart Rhythm. 2015;12:1867-77.
Singh K, Carson K, Hibbert B, Le May M. Natural history of cardiac arrest in patients with takotsubo cardiomyopathy. Am J Cardiol. 2015;115:1466-72.
Sara JD, Lennon RJ, Ackerman MJ, Friedman PA, Noseworthy PA, Lerman A. Coronary microvascular dysfunction is associated with baseline QTc prolongation amongst patients with chest pain and non-obstructive coronary artery disease. J Electrocardiol. 2016;49:87-93.
Magnano AR, Talathoti N, Hallur R, Bloomfield DM, Garan H. Sympathomimetic infusion and cardiac repolarization: the normative effects of epinephrine and isoproterenol in healthy subjects. J Cardiovasc Electrophysiol. 2006;17:983-9.
Neil C, Nguyen TH, Kucia A, Crouch B, Sverdlov A, Chirkov Y, et al. Slowly resolving global myocardial inflammation/oedema in Tako-Tsubo cardiomyopathy: evidence from T2-weighted cardiac MRI. Heart. 2012;98:1278-84.
Stiermaier T, Rommel KP, Eitel C, Möller C, Graf T, Desch S, et al. Management of arrhythmias in patients with Takotsubo cardiomyopathy: is the implantation of permanent devices necessary? Heart Rhythm. 2016;13:1979-86.
Shimizu M, Nishizaki M, Yamawake N, Fujii H, Sakurada H, Isobe M, et al. J wave and fragmented QRS formation during the hyperacute phase in takotsubo cardiomyopathy - possible markers for severity of myocardial damage. Circ J. 2014;78:943-9.
Choi SY, Cho KI, Han YJ, You GI, Kim JH, Heo JH, et al. Impact of pheochromocytoma on left ventricular hypertrophy and QTc prolongation: comparison with Takotsubo cardiomyopathy. Korean Circ J. 2014;44:89-96.
Bennett J, Ferdinande B, Kayaert P, Wiyono S, Goetschalkx K, Dubois C, et al. Time course of electrocardiographic changes in transient left ventricular ballooning syndrome. Int J Cardiol. 2013;169:276-80.
Samuelov-Kinori L, Kinori M, Kogan Y, Swartzon M, Shalev H, Guy D, et al. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes? J Electrocardiol. 2009;42:353-7.
Möller C, Eitel C, Thiele H, Eitel I, Stiermaier T. Ventricular arrhythmias in patients with takotsubo syndrome. J Arrhyth. 2018;34:369-75.
Jha S, Zeijlon R, Enabtawi I, Espinosa AS, Chamat J, Omerovic E, et al. Electrocardiographic predictors of adverse in-hospital outcomes in the Takotsubo syndrome. Int J Cardiol. 2020;299:43-8.
Larsen TR, Kaszala K, Tan AY, Ellenbogen KA, Huizar JF. Paradoxical reflex bradycardia after epinephrine infusion for arrhythmia induction in the electrophysiology laboratory. Heart Case Rep. 2018;4:455-8.
Kido K, Guglin M. Drug-induced Takotsubo cardiomyopathy. J Cardiovasc Pharmacol Ther. 2017;22:552-63.
Nazir S, Lohani S, Tachamo N, Ghimire S, Poudel DR, Donato A. Takotsubo cardiomyopathy associated with epinephrine use: a systematic review and meta-analysis. Int J Cardiol. 2017;229:67-70.
White JL, Kahoud RJ, Li JTC, Campbell RL, Ackerman MJ. Long QT syndrome and life-threatening anaphylaxis: is epinephrine safe? Ann Allergy Asthma Immunol. 2016;117:444-6.
Hajsadeghi S, Rahbar MH, Iranpour A, Salehi A, Asadi O, Jafarian SR. Dobutamine-induced takotsubo cardiomyopathy: a systematic review of the literature and case report. Anatol J Cardiol. 2018;19:412-6.
Margey R, Diamond P, McCann H, Sugrue D. Dobutamine stress echo-induced apical ballooning (Takotsubo) syndrome. Eur J Echocardiogr. 2009;10:395-9.
Sherif K, Sehli S, Jenkins LA. Takotsubo cardiomyopathy after administration of norepinephrine. Baylor Univ Med Cent Proc. 2016;29:166-7.
Laínez B, Ureña M, Alvarez V, Lezaun R. Iatrogenic tako-tsubo cardiomyopathy secondary to catecholamine administration. Rev Esp Cardiol. 2009;62:1498-9.
Quick S, Quick C, Schneider R, Sveric K, Katzke S, Strasser RH, et al. Guillain-Barré syndrome and catecholamine therapy. A potential risk for developing takotsubo cardiomyopathy? Int J Cardiol. 2013;165:E43-4.
Redfors B, Shao Y, Omerovic E. Fatal stress-induced cardiomyopathy in a young patient treated with adrenomimetics. Clin Res Cardiol. 2012;101:939-40.
Vogel SM, Terzic A. α-Adrenergic regulation of action potentials in isolated rat cardiomyocytes. Eur J Pharmacol. 1989;164:231-9.
Tse G, Chan YWF, Keung W, Yan BP. Electrophysiological mechanisms of long and short QT syndromes. IJC Heart Vasc. 2017;14:8-13.
Shao Y, Redfors B, Ståhlman M, Täng MS, Miljanovic A, Möllmann H, et al. A mouse model reveals an important role for catecholamine-induced lipotoxicity in the pathogenesis of stress-induced cardiomyopathy. Eur J Heart Fail. 2013;15:9-22.
Madias JE. Electrocardiogram attenuation of QRS complexes in association with Takotsubo syndrome. Cardiovasc Revascul Med. 2014;15:365.
Migliore F, Zorzi A, Peruzza F, Perazzolo Marra M, Tarantini G, Iliceto S, et al. Incidence and management of life-threatening arrhythmias in Takotsubo syndrome. Int J Cardiol. 2013;166:261-3.
Ali A, Redfors B, Lundgren J, Alkhoury J, Oras J, Gan LM, et al. The importance of heart rate in isoprenaline-induced takotsubo-like cardiac dysfunction in rats. ESC Heart Fail. 2020;7:2690-9.
Surikow SY, Raman B, Licari J, Singh K, Nguyen TH, Horowitz JD. Evidence of nitrosative stress within hearts of patients dying of Tako-tsubo cardiomyopathy. Int J Cardiol. 2015;189:112-4.
Surikow SY, Nguyen TH, Stafford I, Chapman M, Chacko S, Singh K, et al. Nitrosative stress as a modulator of inflammatory change in a model of Takotsubo syndrome. JACC Basic Transl Sci. 2018;3:213-26.
Wilson HM, Cheyne L, Brown PAJ, Kerr K, Hannah A, Srinivasan J, et al. Characterization of the myocardial inflammatory response in acute stress-induced (Takotsubo) cardiomyopathy. JACC Basic Transl Sci. 2018;3:766-78.
Eitel I, Von Knobelsdorff-Brenkenhoff F, Bernhardt P, Carbone I, Muellerleile K, Aldrovandi A, et al. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. JAMA. 2011;306:277-86.
Nguyen TH, Liu S, Ong GJ, Stafford I, Frenneaux MP, Horowitz JD. Glycocalyx shedding is markedly increased during the acute phase of Takotsubo cardiomyopathy. Int J Cardiol. 2017;243:296-9.
Iacucci I, Carbone I, Cannavale G, Conti B, Iampieri I, Rosati R, et al. Myocardial oedema as the sole marker of acute injury in Takotsubo cardiomyopathy: a cardiovascular magnetic resonance (CMR) study. Radiol Med. 2013;118:1309-23.
Sattler S, Couch LS, Harding SE. Takotsubo syndrome: latest addition to the expanding family of immune-mediated diseases? JACC Basic Transl Sci. 2018;3:779-81.
Couch LS, Harding SE. Takotsubo syndrome: stress or NO stress. JACC Basic Transl Sci. 2018;3:227-9.
Scally C, Abbas H, Ahearn T, Srinivasan J, Mezincescu A, Rudd A, et al. Myocardial and systemic inflammation in acute stress-induced (Takotsubo) cardiomyopathy. Circulation. 2019;139:1581-92.
Carnagarin R, Matthews V, Zaldivia MTK, Peter K, Schlaich MP. The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension. Br J Pharmacol. 2019;176:1839-52.
Ederhy S, Dolladille C, Thuny F, Alexandre J, Cohen A. Takotsubo syndrome in patients with cancer treated with immune checkpoint inhibitors: a new adverse cardiac complication. Eur J Heart Fail. 2019;21:945-7.
Shah RM, Shah M, Shah S, Li A, Jauhar S. Takotsubo syndrome and COVID-19: associations and implications. Curr Probl Cardiol. 2021;46:100763.
Dawson DK, Neil CJ, Henning A, Cameron D, Jagpal B, Bruce M, et al. Tako-Tsubo cardiomyopathy: a heart stressed out of energy? JACC Cardiovasc Imaging. 2015;8:985-7.
Ibrahim T, Nekolla SG, Langwieser N, Rischpler C, Groha P, Laugwitz KL, et al. Simultaneous positron emission tomography/magnetic resonance imaging identifies sustained regional abnormalities in cardiac metabolism and function in stress-induced transient midventricular ballooning syndrome: a variant of takotsubo cardiomyopathy. Circulation. 2012;126:e324-6.
Redfors B, Shao Y, Ali A, Omerovic E. Are the different patterns of stress-induced (Takotsubo) cardiomyopathy explained by regional mechanical overload and demand: supply mismatch in selected ventricular regions? Med Hypotheses. 2013;81:954-60.
Redfors B, Shao Y, Ali A, Omerovic E. Are ischemic stunning, conditioning, and ‘takotsubo’ different sides to the same coin? Int J Cardiol. 2014;172:490-1.
Kawaji T, Shiomi H, Morimoto T, Tazaki J, Imai M, Saito N, et al. Clinical impact of left ventricular outflow tract obstruction in takotsubo cardiomyopathy. Circ J. 2015;79:839-46.
Wright PT, Tranter MH, Morley-Smith AC, Lyon AR. Pathophysiology of takotsubo syndrome - temporal phases of cardiovascular responses to extreme stress. Circ J. 2014;78:1550-8.
Sengupta PP, Krishnamoorthy VK, Korinek J, Narula J, Vannan MA, Lester SJ, et al. Left ventricular form and function revisited: applied translational science to cardiovascular ultrasound imaging. J Am Soc Echocardiogr. 2007;20:539-51.
Prinzen FW, Cheriex EC, Delhaas T, van Oosterhout MFM, Arts T, Wellens HJJ, et al. Asymmetric thickness of the left ventricular wall resulting from asynchronous electric activation: a study in dogs with ventricular pacing and in patients with left bundle branch block. Am Heart J. 1995;130:1045-53.
Brutsaert DL. Tako-Tsubo cardiomyopathy. Eur J Heart Fail. 2007;9:854.
Nef HM, Möllmann H, Troidl C, Kostin S, Böttger T, Voss S, et al. Expression profiling of cardiac genes in Tako-Tsubo cardiomyopathy: insight into a new cardiac entity. J Mol Cell Cardiol. 2008;44:395-404.